Back to Journals » Drug Design, Development and Therapy » Volume 12

Monitoring antiangiogenesis of bevacizumab in zebrafish

Authors Zhang J, Gao BL, Zhang WC, Qian ZJ, Xiang Y

Received 23 February 2018

Accepted for publication 2 May 2018

Published 6 August 2018 Volume 2018:12 Pages 2423—2430


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Anastasios Lymperopoulos

Jing Zhang,1,2,* Beili Gao,1,* Wenchao Zhang,1 Zijun Qian,1 Yi Xiang1

1Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Institute of Respiratory Diseases, School of Medicine, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 2Respiratory Department of Shanghai East Hospital Affiliated to Tongji University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Abstract: Bevacizumab, which is a humanized anti-VEGF antibody, has been successfully applied in clinics since 2004. Bevacizumab in combination with chemotherapy showed high safety and has been applied to solid tumors. However, studies on the insight into the mechanism about the antiangiogenesis activity of bevacizumab were mostly done on mice models, and so there are no visual and intuitive models to observe the process of antiangiogenesis. Here, we first used a zebrafish model to investigate the angiogenesis suppressing behavior of bevacizumab. Our results showed that bevacizumab inhibited formation of zebrafish subintestinal veins, which mimics the process of tumor angiogenesis in vivo. Meanwhile, bevacizumab caused specific vasculature formation defects in subintestinal veins but not in the trunk. Our study also indicated that bevacizumab could inhibit zebrafish retinal angiogenesis with therapeutic potential.

Keywords: zebrafish, bevacizumab, anti-angiogenesis, VEGF, subintestinal vein

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]